Cong Claire Xu - 30 Aug 2026 Form 4 Insider Report for NovaBridge Biosciences (NBP)

Reporting relationship: EVP, Clinical Development
Issuer ticker: NBP
Reported as of: 30 Aug 2026
Net transaction value: -$2,593
SEC form: 4
Accepted by SEC: 01 Sep 2026, 18:00:08 UTC
Prior SEC filing: 07 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Kyler Lei, Attorney-in-Fact

Key filing fact

Cong Claire Xu filed Form 4 for NovaBridge Biosciences (NBP) on 01 Sep 2026.

Key facts

This page summarizes Cong Claire Xu's Form 4 filing for NovaBridge Biosciences (NBP).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Sep 2026, 18:00.

Change

Previous filing in this sequence was filed on 07 Jul 2026.
Current net transaction value: -$2,593.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002114309 Primary reporting owner

Xu Cong Claire

Relationship: EVP, Clinical Development
Address: C/O NOVABRIDGE BIOSCIENCES, 2440 RESEARCH BOULEVARD, SUITE 400, ROCKVILLE
Signature: /s/ Kyler Lei, Attorney-in-Fact
Signature date: 01 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NBP transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +9,382
Change %: +3.1%
Price
Shares after: 307,483
Date: 30 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

NBP transaction

Ordinary Shares

Sale

Transaction value: $2,593
Shares: -3,282
Change %: -1.1%
Price: $0.7900
Shares after: 304,201
Date: 31 Aug 2026
Ownership: Direct
Footnotes: F1, F5, F6, F7

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBP transaction Derivative

Restricted Share Units

Options Exercise

Transaction value
Shares: -4,079
Change %: -12%
Price: $0.000000^*
Shares after: 28,558
Date: 30 Aug 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 4,079
Exercise price
Footnotes: F1, F3, F8, F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

Footnote F2

Reported securities are represented by 4,079 ADSs.

Footnote F3

Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

Footnote F4

Reported securities are represented by 133,688 ADSs.

Footnote F5

Reported securities are represented by 1,427 ADSs.

Footnote F6

Reported sales price represents the converted sales price of the ADSs of $1.8186.

Footnote F7

Reported securities are represented by 132,261 ADSs.

Footnote F8

Reported securities represent ADSs.

Footnote F9

On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.